Cambridge startup Intellegens has secured a landmark maiden deal for its Alchemite artificial intelligence technology. The company has revealed its first commercial collaboration – with e-Therapeutics, an Oxford-based pioneer of Network-Driven Drug Discovery. Alchemite will enable e-Therapeutics to generate improved predictions, correct errors and fill in gaps in the large-scale biological and chemical information repositories housed in the company's proprietary databases. Alchemite is the result of intensive research by Dr Gareth Conduit, CTO and Intellegens co- founder. Working at the world-famous Cavendish Laboratories in Cambridge, Dr Conduit discovered a new method of analysing sparsely populated matrices using deep neural networks and novel machine learning approaches.